Rare Kidney Diseases Market Report 2026

The rare kidney diseases market size has grown strongly in recent years. It will grow from $3.03 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to limited treatment options for rare renal disorders, growing awareness of genetic kidney diseases, increasing prevalence of autoimmune-related nephropathies, expansion of nephrology specialty care centers, early adoption of immunosuppressive therapies.

The rare kidney diseases market size is expected to see rapid growth in the next few years. It will grow to $4.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advances in genomics-based drug discovery, rising orphan drug approvals, increasing investment in rare disease research, growing use of personalized medicine approaches, expanding pipeline of complement and immune-targeted therapies. Major trends in the forecast period include rising focus on targeted therapies for rare renal disorders, increasing clinical trial activity for orphan kidney drugs, growing adoption of biologics in immune-mediated kidney diseases, expansion of companion diagnostics for early disease detection, increasing regulatory incentives for rare disease drug development.

The rising prevalence of chronic kidney disease (CKD) is significantly driving growth in the rare kidney disease market. CKD is a disorder in which the kidneys are damaged and unable to properly filter blood. The increasing occurrence of CKD raises the likelihood of developing rare kidney diseases, thereby boosting demand for specialized therapeutics. For example, in August 2025, the National Kidney Foundation, Inc., a US-based nonprofit health organization, reported that the Senate approved a $5 million increase in the FY 2026 Labor, Health and Human Services, and Education appropriations bill to support kidney transplant reform and early detection initiatives. This brings total funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Consequently, the growing prevalence of CKD is expected to propel the rare kidney disease market.

Key players in the rare kidney disease market are focusing on developing non-immunosuppressive therapies to treat these conditions. Non-immunosuppressive therapies offer treatment options for progressive kidney diseases that conventional therapies cannot address. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched sparsentan, commercially known as Filspari. Filspari is the first non-immunosuppressive therapy approved for primary immunoglobulin A nephropathy (IgAN). It functions by blocking angiotensin and endothelin receptors, distinguishing it from ACE inhibitors and ARBs, which are typically prescribed for hypertension and have been repurposed for IgAN due to their kidney blood-pressure-lowering effects.

In February 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition strengthens AstraZeneca’s portfolio in chronic renal illnesses and uncontrolled hypertension. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, develops therapies for rare kidney diseases.

Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.

North America was the leading region in the rare kidney disease market in 2025. The regions covered in the rare kidney diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare kidney diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the rare kidney diseases market by increasing the cost of imported active pharmaceutical ingredients, biologics manufacturing inputs, and specialized laboratory equipment used in drug development and diagnostics. These cost pressures have affected biologics and complement inhibitor segments more significantly, with Asia-Pacific and parts of Europe experiencing supply chain disruptions due to reliance on cross-border sourcing. However, tariffs have also encouraged pharmaceutical companies to localize manufacturing, strengthen regional supply chains, and invest in domestic production capabilities, supporting long-term market resilience and innovation.

The rare kidney diseases market research report is one of a series of new reports that provides rare kidney diseases market statistics, including rare kidney diseases industry global market size, regional shares, competitors with a rare kidney diseases market share, detailed rare kidney diseases market segments, market trends and opportunities, and any further data you may need to thrive in the rare kidney diseases industry. This rare kidney diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare kidney disease refers to a condition in which the kidneys do not function properly, leading to waste buildup in the body and associated health problems. These are a group of renal disorders with low prevalence in the general population, often with a genetic or hereditary basis.

The main types of rare kidney diseases include IgA nephropathy, lupus nephritis, focal segmental glomerular sclerosis, membranous nephropathy, C3 glomerulopathy, and others. IgA nephropathy is a kidney condition in which antibodies called IgA accumulate in kidney tissue, causing inflammation. Treatments such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are used to lower blood pressure, reduce protein loss, slow disease progression, manage symptoms, and prevent complications. Therapeutic approaches involve small molecules and biologics, administered through various routes including oral, intravenous, subcutaneous, and others.

The rare kidney disease market includes revenues earned by entities by providing services clinical evaluation, genetic counseling, genetic screening, specific testing, molecular diagnosis, hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.